OmniActive’s proprietary blend supports joint comfort and mobility, study finds
Muvz Supports Mobility and Musculoskeletal Health in Active Adults
Bridgewater, N.J. and Mumbai, India (March 12, 2025)—Today, OmniActive Health Technologies (OmniActive), a leading global supplier of ingredient solutions for the nutrition, health, and wellness industries, announces the publication of a peer-reviewed clinical study demonstrating the positive effects of Muvz for improving mobility and supporting joints. The study, A Randomized, Placebo-Controlled Dose-Response Trial of Muvz for Knee and Low-Back Support in Physically Active Adults, was published in Drug Design, Development and Therapy (Dovepress Taylor & Francis Group).
The three-month double-blind study involved 157 adults aged 40-60 years and evaluated the effectiveness of Muvz at two different dosages: 200 mg (low dose) and 200 mg twice a day (high dose). The study found that supplementation with Muvz at both doses significantly improved musculoskeletal health questionnaire scores starting at day 30, supported joint and low-back comfort, reduced discomfort after physical activity, and enhanced both active and passive flexion range of motion by day 90.
“We are excited to see this new publication validating the benefits of Muvz in supporting joint and low-back comfort with improved mobility, particularly for those with knee and lower back discomfort,” said Abhijeet Morde, Senior Director of Invitro Biology, Animal Studies, and Clinicals at OmniActive. “The results align with previous studies, further reinforcing Muvz as a natural, ingredient solution for supporting mobility through joint and low-back comfort support as well as flexibility in physically active individuals.”
The study’s findings add to the clinical foundation of Muvz’s efficacy as a valuable ingredient for joint and mobility formulations, particularly for the growing market of adults seeking natural solutions to support mobility.
“The global joint health market sits at over $11.5 billion, which is being propelled by younger, active consumers and athletes†,” said Keya Shah, Assistant Director leading OmniActive’s joint health category. “Muvz continues to demonstrate significant benefits for mobility and with this new research, we’re well-positioned to meet the growing demand for high-quality plant-based ingredients that may help support consumers of various activity levels who are looking for better mobility and improved quality of life.”
Muvz is a proprietary blend of two botanicals, Vitex negundo and Zingiber officinale, known for their analgesic, anti-inflammatory, and antioxidant properties, and is now an OmniActive product following the acquisition of ENovate Biolife. For more details on Muvz, visit omniactives.com, or for more information on the study, see the study link.
About OmniActive
Established in 2005, OmniActive seeks to improve lives through innovative science and natural health solutions. OmniActive’s product portfolio consists of scientifically validated, IP-protected, branded Specialty Actives and an extensive portfolio of natural Botanical Actives for global customers in the dietary supplement, functional food, and beverage markets. The company has offices in Mumbai, India, and Bridgewater, New Jersey.
†Future Market Insights, Bone and Joint Health Supplement Market – Growth & Market Insights, 2024. https://www.futuremarketinsights.com/reports/bone-and-joint-health-supplement-market
Media Contact
Meredith Kish
+1-973-202-4034